Lintzeris, Nicholas
Mills, Llewellyn
Abelev, Sarah V.
Suraev, Anastasia
Arnold, Jonathon C.
McGregor, Iain S.
Article History
Received: 1 May 2022
Accepted: 19 July 2022
First Online: 30 July 2022
Declarations
:
: This study was approved by the Sydney University Human Research ethics Committee (2018/544). In order to begin the survey, participants were asked to read a linked Participant Information Statement and to tick a check box giving consent for their data to be used in the study.
: Not applicable.
: Prof Lintzeris reports grants from the Australian National Health and Medical Research Council (NHMRC) during the conduct of the study; and research grants from Camurus and Indivior for unrelated work. A/Prof Arnold and Prof McGregor report grants from NHMRC and grants from Lambert Initiative for Cannabinoid Therapeutics during the conduct of the study for projects unrelated to the submitted work; Dr McGregor has patents to WO2018107216A1, WO2017004674A1 and WO2011038451A1 issued and licensed. A/Prof Arnold and Prof McGregor have patents to AU2017904438, AU2017904072 and AU2018901971 pending. No other authors report conflicts of interest.